Today: 12 March 2026
Oracle Stock Price Jumps After AI Cloud Forecast Eases Debt Fears

Oracle Stock Price Jumps After AI Cloud Forecast Eases Debt Fears

NEW YORK, March 12, 2026, 09:10 EDT

Oracle finished March 11 at $163.12, surging 9.18% after the company raised its fiscal 2027 revenue outlook and pointed to sustained demand for AI-driven cloud services. That jump wiped out recent losses for the stock. Bloomberg.com

Oracle’s been feeling the squeeze from the hefty price tag on AI data centers, with major clients like OpenAI and Meta in the mix. Shares bounced back on Wednesday, a sign investors took the fresh results as proof those investments could finally be delivering. Reuters

Oracle reported a 325% jump in remaining performance obligations from a year ago, climbing to $553 billion—these are revenues locked in but not yet recognized. The company bumped up its fiscal 2027 revenue outlook to $90 billion, while sticking with earlier forecasts for fiscal 2026: $67 billion in revenue and $50 billion in capital spending. Oracle Investor Relations

Oracle posted a 22% bump in total revenue for the quarter ended Feb. 28, hitting $17.2 billion. Cloud revenue surged 44% to $8.9 billion, while Oracle Cloud Infrastructure rocketed up 84% to $4.9 billion. Adjusted earnings per share landed at $1.79. Looking ahead, the company is projecting fourth-quarter cloud revenue growth of 46% to 50% in U.S. dollars. Oracle

eMarketer analyst Jacob Bourne described the numbers as a “stress test result for the AI trade.” Oracle executive Clay Magouyrk, speaking on the earnings call, noted that the cloud unit’s margin profile “continues to strengthen,” pointing to growth in higher-margin database services alongside demand for AI-chip rentals. Reuters

The funding snag isn’t gone. Oracle reported that a good chunk of its fresh AI deals come with customer prepayments or customers bringing their own GPUs—the chips essential for AI work. The company also said it has pulled in $30 billion so far after setting out to raise as much as $50 billion in debt and equity. Oracle Investor Relations

The financing question isn’t fading, according to Matt Britzman, senior equity analyst at Hargreaves Lansdown. Even as Oracle’s revamped contract structure could help the company scale up without footing the entire hardware bill, the issue lingers. Morgan Stanley analysts struck a more reserved tone. Investors, they wrote, are still waiting for firmer evidence that Oracle’s GPU-as-a-service business—essentially, leasing high-end AI chips in the cloud—will actually bolster earnings and free cash flow. Oracle’s credit default swaps, which measure the cost for investors to insure against a default, surged to record highs earlier this month before pulling back, Reuters reported. Reuters

Oracle is jockeying for a bigger piece of the AI cloud action, looking to draw AI workloads away from Amazon Web Services and Microsoft Azure. At the same time, it’s fending off worries that AI-powered coding could chip away at the core software-as-a-service business. Larry Ellison shrugged off the threat, arguing that the SaaS-apocalypse “applies to others but not to Oracle.” Ocean Park Asset Management’s James St. Aubin pointed to proprietary data as the “deepest moat by far.” Reuters

Rebecca Wettemann, CEO at Valoir, pointed out that Oracle’s database is compatible with all the leading clouds—letting customers pick where to run workloads as AI expands across different platforms. This flexibility sits at the heart of Oracle’s strategy: instead of matching the top cloud providers dollar for dollar, the company relies on its massive database user base. Reuters

The next hurdle is just ahead. Oracle is forecasting fourth-quarter revenue growth between 19% and 21%, with adjusted earnings pegged at $1.96 to $2.00 per share. Wall Street wants more clarity on whether demand, margins, and funding are lining up. Oracle Investor Relations

Stock Market Today

  • Nintendo Shares Jump 18% as Surprise Hit 'Pokémon Pokopia' Boosts Switch 2 Sales Hopes
    March 12, 2026, 9:42 AM EDT. Nintendo's shares surged 18% this week following the unexpected success of "Pokémon Pokopia," which sold 2.2 million units in its first four days. The game, exclusive to the Switch 2 console launched last year, ranks as the fourth-best-selling title on the system. Investors are optimistic that this hit could accelerate Switch 2 sales, aligning with Nintendo's fiscal year sales forecast of 19 million units. Despite the rally, Nintendo's stock remains down about 28% over six months amid concerns over rising memory costs affecting margins. Analysts noted "Pokémon Pokopia" combines deep gameplay and multiplayer features, adding notable momentum to Nintendo's gaming lineup.

Latest article

Oracle Stock Price Jumps After AI Cloud Forecast Eases Debt Fears

Oracle Stock Price Jumps After AI Cloud Forecast Eases Debt Fears

12 March 2026
Oracle shares jumped 9.18% to $163.12 after the company raised its fiscal 2027 revenue target to $90 billion and reported a 325% surge in remaining performance obligations to $553 billion. Quarterly cloud revenue rose 44% to $8.9 billion. Oracle said many new AI contracts are backed by customer prepayments or client-supplied GPUs. Financing concerns remain despite $30 billion already raised toward a $50 billion target.
Why American Airlines Group Inc. Stock Is Stuck Near $11 as Oil Tops $100

Why American Airlines Group Inc. Stock Is Stuck Near $11 as Oil Tops $100

12 March 2026
American Airlines shares fell 0.6% to $11.04 Thursday as oil briefly topped $100 a barrel after new Gulf shipping attacks. Jet fuel prices have doubled since the Iran conflict began, squeezing airline margins. American is more exposed than rivals due to a lack of fuel hedging. The carrier will present at J.P. Morgan’s Industrials Conference on March 17.
Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

12 March 2026
Hims & Hers Health shares climbed 5.1% to $27.19 in premarket trading Thursday, after closing up 10.3% Wednesday. The rally follows a deal with Novo Nordisk that ends a patent dispute and will return FDA-approved Wegovy and Ozempic to Hims’ platform later this month. Analysts raised targets but warned branded drugs may bring lower margins. Hims also disclosed an SEC probe and a Justice Department referral.
Why American Airlines Group Inc. Stock Is Stuck Near $11 as Oil Tops $100
Previous Story

Why American Airlines Group Inc. Stock Is Stuck Near $11 as Oil Tops $100

Go toTop